Guidelines for cervical cancer screening: History and scientific rationale

Clinical Obstetrics and Gynecology

Volumn 48, Issue 1, 2005, Pages 77-97

  Waxman, Alan G ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; CONFERENCE PAPER; HUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; AGED; FEMALE; HEALTH PLANNING GUIDELINES; HISTORY, 20TH CENTURY; HUMANS; MASS SCREENING; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 14844350953     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000151590.08451.26     Document Type: Conference Paper

References (69)

1. American Cancer Society. Cancer Facts and Figures 2004. Available at: http://www. cancer.org/docroot/STT/content/STT_lx_ Cancer_Facts_Figures_2004. asp. Accessed June 6, 2004.
2. Reis LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975-2001. National Cancer Institute. Available at: http://seer. cancer.gov/cst/1975_2001/. Accessed June 20, 2004.
3. Hammond EC, Seidman H. Progress in control of cancer of the uterus. Arch Environ Health. 1966;13:105-116.
4. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol. 1999;94:307-310.
5. International Agency for Research on Cancer. Globocan 2000 Database: Cancer incidence, mortality and prevalence worldwide. World Health Organization. 2002. Available at: http://www-dep.iarc.fr/globocan/globocan.html. Accessed June 20, 2004.
6. Muñoz N, Bosch X, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
7. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001;79:954-962.
8. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102:3-8.
9. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;84:1616-1623.
10. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002; 288:1749-1757.
11. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr. 1996;21:17-25.
12. McRory DC, Batcher DB, Bastian L, et al. Evaluation of Cervical Cytology: Evidence Report/Technology Assessment No. 5. Rockville, MD: Agency for Healthcare Policy and Research; 1999: AHCPR Publication no. 99-E010.
13. Barter JF. The life and contributions of Doctor George Nicholas Papanicolaou. Surg Gynecol Obstet. 1992;174:530-532.
14. Vilos GA. Dr. George Papanicolaou and the birth of the Pap test. Obstet Gynecol Surv. 1999;54:481-483.
15. Shaw PA. The history of cervical screening I: the Pap test. J Soc Obstet Gynaecol Can. 2000;22:110-114.
16. Babes A. Diagnosis of cancer of the uterine cervix by smears. Acta Cytol. 1967;11: 217-224.
17. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42: 193-206.
18. American Cancer Society. Guidelines for the cancer related checkup: recommendations and rationale. CA Cancer J Clin. 1980;30: 195-230.
19. Burns EL, Hammond EC, Percy C, et al. Detection of uterine cancer. Results of a community program of 17 years. Cancer. 1968;22:1108-1119.
20. Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in British Columbia. J Obstet Gynaec Br Commonw. 1968;75: 392-404.
21. Christopherson WM, Mendez WM, Ahuja EM, et al. Cervix cancer control in Louisville, Kentucky. Cancer. 1970;26:29-38.
22. The American College of Obstetricians and Gynecologists. Manual of Standards in Obstetric-Gynecologic Practice. 1st ed. Chicago, IL: ACOG; 1959.
23. The American College of Obstetricians and Gynecologists. Manual of Standards in Obstetric-Gynecologic Practice. 2nd ed. Chicago, IL: ACOG; 1965.
24. Walton RJ, Blanchet M, Boyes DA, et al. Cervical cancer screening programs. Department of National Health and Welfare Task Force report. Can Med Assoc J. 1976;114: 1003-1033.
25. American College of Obstetricians and Gynecologists. The Frequency With Which a Cervical-Vaginal Cytology Examination Should Be Performed in Gynecologic Practice. ACOG Technical Bulletin, No. 29. Chicago, IL: ACOG; 1975.
26. American College of Obstetrics and Gynecologists. Periodic Cancer Screening for Women. ACOG Statement of Policy. Washington, D.C.: ACOG; 1980.
27. Fink DJ. Change in American cancer society checkup guidelines for detection of cervical cancer. CA Cancer J Clin. 1988;38:127-128.
28. American College of Obstetrics and Gynecologists. Recommendations on Frequency of Pap Test Screening. ACOG Committee Opinion No. 152. Washington, D.C.: ACOG; 1995.
29. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
30. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79: 328-337.
31. Ho GY, Bierman R, Beardsley L, et al. The natural history of cervical papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
32. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
33. Schlect NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
34. Moscicki AB, Burt VG, Kanowitz S, et al. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer. 1999;85:1139-1144.
35. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer. 1995;76:1888-1901.
36. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
37. American College of Obstetrics and Gynecologists. Cervical cytology screening. ACOG Practice Bulletin No. 45. Obstet Gynecol. 2003;102:417-427.
38. U.S. Preventative Services Task Force. Screening for cervical cancer. Agency for Healthcare Research and Quality. 2003. Available at: http://www.ahrq.gov/clinic/3r-duspstf/cervcan/cervcanwh.pdf. Accessed June 19, 2004.
39. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-192.
40. Moscicki AB. Cervical cytology screening in teens. Curr Womens Health Rep. 2003; 3:433-437.
41. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
42. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics. 1999;103:539-545.
43. Syrjänen K, Kataja V, Yliskoski M, et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol. 1992;79:675-682.
44. Nasiell K, Nasiell M, Vaćlavinková V. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol. 1986;67:665-669.
45. Hartmann KE, Nanda K, Hall S, et al. Technologic advances for evaluation of cervical cytology: is newer better? Obstet Gynecol Surv. 2001;56:765-774.
46. Nobbenhuis MAE, Meijer CJLM, van den Brule AJC, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 2001; 84:796-801.
47. Mitchell MF, Tortorlero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998;92:737-744.
48. Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med. 2003; 349:1501-1509.
49. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed). 1986; 293:659-664.
50. Sawaya GF, Kerlikowske K, Lee NC, et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000;96:219-223.
51. Miller MG, Sung HY, Sawaya GF, et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol. 2003;101:29-37.
52. Pearce KF, Haefner HK, Sarwar SF, et al. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med. 1996; 335:1559-1562.
53. Fetters MD, Fischer G, Reed B. Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. JAMA. 1996;275:940-947.
54. Aho M, Vesterinin E, Meyer B, et al. Natural history of vaginal intraepithelial neoplasia. Cancer. 1991;68:195-197.
55. Kalogirou D, Antoniou G, Karakitsos P, et al. Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. Eur J Gynaecol Oncol. 1997;18:188-191.
56. Piscitelli JT, Bastian LA, Wilkes A, et al. Cytologic screening after hysterectomy for benign disease. Am J Obstet Gynecol. 1995; 173:424-430.
57. Sawaya GF. Should routine screening Papanicolaou smears be done for women older than 65 years? Arch Intern Med. 2004;164: 243-245.
58. Cervical cancer. NIH Consens Statement. 1996;14:1-38.
59. Sellers JW, Karwalajtys TL, Kaczorowski JA, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. Can Med Assoc J. 2002;167: 871-873.
60. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997;1:362-375.
61. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55:244-265.
62. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
63. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003;127:959-968.
64. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
65. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619-631.
66. Wright TC Jr, Cox JT, Massed LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
67. Cox JT, Schiffman M, Solomon D, et al. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
68. Bates B. ACOG: annual Pap not for all women. Ob/Gyn News. 2003;38:1-4.
69. American College of Obstetricians and Gynecologists. Primary and Preventive Care: Periodic Assessments. ACOG Committee Opinion No. 292. Washington, D.C.: ACOG; 2003.